Repare Therapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Repare Therapeutics announced a definitive agreement to be acquired by XenoTherapeutics, with shareholders receiving cash and contingent value rights.
Repare Therapeutics announced a net loss of $16.7 million for Q2 2025, compared to a net loss of $34.8 million in Q2 2024.
Repare Therapeutics reports Q1 2025 results, highlighted by a strategic shift towards clinical programs and cost-saving measures, including workforce reductions and out-licensing of discovery platforms.
Repare Therapeutics announced its Q3 2024 results, highlighting a strategic shift towards clinical-stage programs and providing updates on its key drug candidates.
10-Q: Repare Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Repare Therapeutics reported its second quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.
Repare Therapeutics reported a net income of $13.2 million for the first quarter of 2024, primarily driven by collaboration revenue, particularly from the Roche agreement.